Flare Therapeutics Inc. will receive $70 million in cash up front from Roche Holding AG, and the deal could ultimately bring the company about $1.8 billion plus royalties. Flare will search for small molecules that can be used to treat undruggable transcription factors to treat cancer. Also, Novartis AG will pay computational-chemistry expert Schrödinger Inc. $150 million up front and as much as $2.3 billion in milestones to develop several candidates along with up to $892 million in R&D and milestone payments. Read More
More than two years since emerging from stealth, Vesalius Therapeutics Inc. signed its first major pharma deal with GSK plc. Worth up to $650 million and possibly more if an option is exercised, the multitarget alliance aims to discover and develop novel treatments for Parkinson’s disease and another neurodegenerative indication. Read More
Antelope Surgical Solutions Inc. has received commercial IND approval from the FDA for its novel prostate cancer technology, AS-1986NS. AS1986NS, a fluorescent and lutetium-175 bearing drug, will be evaluated in trials with the aim of addressing prostate cancer identification and surgical margin delineation. Read More
At the annual meeting of the American Society for Human Genetics, scientists presented three new cases of Kabuki syndrome presented with developmental delay, autism and myopia as the common traits. Read More
CSPC Pharmaceutical Group Ltd.’s SYS-6026 has obtained clearance from China’s National Medical Products Administration (NMPA) to enter clinical trials for the treatment of high-grade squamous intraepithelial lesions associated with human papillomavirus (HPV) type 16 or 18. Read More
4M Therapeutics Inc. has been awarded a $120,000 grant from SynGAP Research Fund (SRF) to evaluate central nervous system (CNS) effects of novel glycogen synthase kinase 3 β (GSK-3β) inhibitors 4MT-2001 and 4MT-1060. Read More
Cstone Pharmaceuticals Co. Ltd. presented preclinical data of CS-2009, a trispecific antibody targeting PD-1, CTLA-4 and VEGF-A, for cancer immunotherapy. Read More
The immunological targeting of cold tumors still remains a challenge. Cytokine therapy is promising but has modest efficacy and significant toxicity. Read More
China Hinye Pharmaceutical Co. Ltd. has identified pyrrole sulfonyl compounds and deuterated derivatives acting as H+/K+-ATPase inhibitors reported to be useful for the treatment of peptic ulcers, Zollinger-Ellison syndrome, gastroesophageal reflux disease, dyspepsia, reflux esophagitis, Barrett esophagus, Helicobacter pylori infection and gastric cancer. Read More
Orofacial clefting is a common birth defect that affects 1 in 700 newborns, and includes cleft lip, cleft palate and cleft lip and palate, with a strong genetic component, thus being highly heritable. Researchers have identified new gene variants tied to orofacial clefting. Read More
Genosco Inc. has divulged Rho-associated protein kinase 2 (ROCK2) inhibitors reported to be useful for the treatment of fibrosis, cancer, cardiovascular and inflammatory disorders. Read More
CK1α serves as an upstream regulator of the p53 pathway, and its degradation may facilitate cell death by preventing MDM2 and/or MDMX mediated inactivation of p53. Read More
Shenzhen Salubris Pharmaceuticals Co. Ltd. has described tertiary amine compounds reported to be useful for the treatment of stroke, atherosclerosis, thrombosis, coronary heart disease and aortic valve stenosis. Read More
